Comment on “Photodynamic Therapy Induced Mitochondrial Targeting Strategies for Cancer Treatment: Emerging Trends and Insights” DOI
David Kessel

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 22(1), P. 583 - 584

Published: Dec. 5, 2024

InfoMetrics Molecular PharmaceuticsASAPArticle CiteCitationCitation and abstractCitation referencesMore citation options ShareShare onFacebookX (Twitter)WeChatLinkedInRedditEmailJump toExpandCollapse CommunicationDecember 5, 2024Comment on "Photodynamic Therapy Induced Mitochondrial Targeting Strategies for Cancer Treatment: Emerging Trends Insights"Click to copy article linkArticle link copied!David Kessel*David KesselDepartment of Pharmacology, Wayne State University School Medicine, Detroit, Michigan 48201, United States*Email: [email protected]More by David Kesselhttps://orcid.org/0000-0002-3221-9299Other Access OptionsMolecular PharmaceuticsCite this: Mol. Pharmaceutics 2024, XXXX, XXX, XXX-XXXClick citationCitation copied!https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.4c00385https://doi.org/10.1021/acs.molpharmaceut.4c00385Published December 2024 Publication History Received 9 April 2024Accepted 3 2024Revised 21 October 2024Published online 5 2024rapid-communication© American Chemical SocietyRequest reuse permissionsACS Publications© Society Subjectswhat are subjectsArticle subjects automatically applied from the ACS Subject Taxonomy describe scientific concepts themes article.AssaysFree radicalsMitochondriaPeptides proteinsPhotosensitization Note: In lieu an abstract, this is article's first page. Read To access article, please review available below. Get instant Purchase 48 hours. Check out below using your ID or as a guest. Restore my guest Recommended through Your Institution You may have institution. institution does not content. Add change let them know you'd like include access. Through Recommend Name Loading Institutional Login Options... Change Explore subscriptions institutions Log in with if you previously purchased it member benefits. hours $48.00 cart Checkout Cited By Click section linkSection copied!This has yet been cited other publications.Download PDF e-AlertsGet e-AlertsMolecular copied!https://doi.org/10.1021/acs.molpharmaceut.4c00385Published 2024© permissionsArticle Views-Altmetric-Citations-Learn about these metrics closeArticle Views COUNTER-compliant sum full text downloads since November 2008 (both HTML) across all individuals. These regularly updated reflect usage leading up last few days.Citations number articles citing calculated Crossref daily. Find more information counts.The Altmetric Attention Score quantitative measure attention that research received online. Clicking donut icon will load page at altmetric.com additional details score social media presence given article. how calculated.Recommended Articles

Language: Английский

Ruthenium(II) Polypyridyl Complexes Containing COUBPY Ligands as Potent Photosensitizers for the Efficient Phototherapy of Hypoxic Tumors DOI

Diego Abad-Montero,

Albert Gandioso, Eduardo Izquierdo‐García

et al.

Journal of the American Chemical Society, Journal Year: 2025, Volume and Issue: 147(9), P. 7360 - 7376

Published: Feb. 15, 2025

Hypoxia, a hallmark of many solid tumors, is linked to increased cancer aggressiveness, metastasis, and resistance conventional therapies, leading poor patient outcomes. This challenges the efficiency photodynamic therapy (PDT), which relies on generation cytotoxic reactive oxygen species (ROS) through irradiation photosensitizer (PS), process partially dependent levels. In this work, we introduce novel family potent PSs based ruthenium(II) polypyridyl complexes with 2,2′-bipyridyl ligands derived from COUPY coumarins, termed COUBPYs. Ru-COUBPY exhibit outstanding in vitro cytotoxicity against CT-26 cells when irradiated light within phototherapeutic window, achieving nanomolar potency both normoxic hypoxic conditions while remaining nontoxic dark, impressive phototoxic indices (>30,000). Their ability generate Type I II ROS underpins their exceptional PDT efficiency. The lead compound study, SCV49, shows favorable vivo pharmacokinetic profile, excellent toxicological tolerability, tumor growth inhibition mice bearing subcutaneous tumors at doses as low 3 mg/kg upon deep-red (660 nm). These results allow us propose SCV49 strong candidate for further preclinical development, particularly treating large tumors.

Language: Английский

Citations

2

Mitochondrial signaling pathways and their role in cancer drug resistance DOI
Ashwani Sharma, Tarun Virmani, Girish Kumar

et al.

Cellular Signalling, Journal Year: 2024, Volume and Issue: 122, P. 111329 - 111329

Published: Aug. 5, 2024

Language: Английский

Citations

8

Recent advances in reactive oxygen species (ROS)-responsive drug delivery systems for photodynamic therapy of cancer DOI Creative Commons
Danrong Hu, Yicong Li, Ran Li

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(12), P. 5106 - 5131

Published: Nov. 2, 2024

Reactive oxygen species (ROS)-responsive drug delivery systems (DDSs) have garnered significant attention in cancer research because of their potential for precise spatiotemporal release tailored to high ROS levels within tumors. Despite the challenges posed by distribution heterogeneity and endogenous supply constraints, this review highlights strategic alliance ROS-responsive DDSs with photodynamic therapy (PDT), enabling selective leveraging PDT-induced enhanced therapeutic efficacy. This delves into biological importance progression treatment. We elucidate detail operational mechanisms linkers, including thioether, thioketal, selenide, diselencide, telluride aryl boronic acids/esters, as well latest developments nanomedicines that integrate PDT strategies. These insights are intended inspire design innovative nanocarriers PDT.

Language: Английский

Citations

6

Revolutionizing rheumatoid arthritis treatment with emerging cutaneous drug delivery systems: overcoming the challenges and paving the way forward DOI Creative Commons
Sakshi Priya,

Kaushal Kamal Jain,

Jeevika Daryani

et al.

Nanoscale, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Overview of the ongoing trends in targeting strategies drugs via topical and transdermal delivery futuristic approaches world drug for management rheumatoid arthritis. Images are created with Biorender.com.

Language: Английский

Citations

5

Targeting Sub-Cellular Organelles for Boosting Precision Photodynamic Therapy DOI
G. Attar,

M. Kumar,

Vandana Bhalla

et al.

Chemical Communications, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Among various cancer treatment methods, photodynamic therapy has received significant attention due to its non-invasiveness and high efficiency in inhibiting tumour growth. Recently, specific organelle targeting photosensitizers have increasing interest their precise accumulation ability trigger organelle-mediated cell death signalling pathways, which greatly reduces the drug dosage, minimizes toxicity, avoids multidrug resistance, prevents recurrence. In this review, recent advances representative used targeted on organelles, specifically including endoplasmic reticulum, Golgi apparatus, mitochondria, nucleus, lysosomes, been comprehensively reviewed with a focus structure pathways. Furthermore, perspective future research potential challenges precision presented at end.

Language: Английский

Citations

4

Acid-activatable photosensitizers for photodynamic therapy using self-aggregates of chlorophyll‒peptide conjugates DOI Creative Commons

Miyu Nagatani,

Masaru Yoshikawa, Shinya Tsukiji

et al.

Polymer Journal, Journal Year: 2024, Volume and Issue: 57(1), P. 119 - 128

Published: Sept. 19, 2024

Language: Английский

Citations

4

Applications and challenges of photodynamic therapy in the treatment of skin malignancies DOI Creative Commons

Yunqi Hua,

Xiaoling Tian,

Xinyi Zhang

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Sept. 19, 2024

Photodynamic Therapy (PDT), as a minimally invasive treatment method, has demonstrated its distinct advantages in the management of skin malignant tumors. This article examines current application status PDT, assesses successful cases and challenges clinical treatment, anticipates future development trends. PDT utilizes photosensitizers to interact with light specific wavelengths generate reactive oxygen species that selectively eradicate cancer cells. Despite PDT’s exceptional performance enhancing patients’ quality life prognosis, limitation depth side effects remain unresolved issues. With advancement novel innovative technology, prospects are increasingly expansive. delves into mechanism various malignancies, limitations, envisions development. We believe through continuous technological enhancements integration other technologies, potential assume more pivotal role malignancies.

Language: Английский

Citations

4

Regulated cell death mechanisms in mitochondria-targeted phototherapy DOI
Qihang Ding, Hyeonji Rha,

Changyu Yoon

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: unknown, P. 113720 - 113720

Published: April 1, 2025

Language: Английский

Citations

0

Win-win integration: A mitochondria targeted AIE photosensitizer for hypochlorite detection and type I & type II photodynamic therapy DOI

Jiahao Ni,

L.H. Yu, Yixuan Wang

et al.

Analytica Chimica Acta, Journal Year: 2024, Volume and Issue: 1320, P. 343035 - 343035

Published: July 28, 2024

Language: Английский

Citations

3

Revolutionizing Cancer Management: Cutting-Edge Techniques for Nanophotosensitizer Delivery in Photodynamic Therapy DOI

Shrushti Bhamble,

Keshav Kumar,

Pranayee Datta

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106665 - 106665

Published: Feb. 1, 2025

Language: Английский

Citations

0